Contact us

If you have a question about a medical condition, consult with a healthcare professional or, in the case of an emergency, call your region's emergency services number immediately.

If you have a question about any of the content presented here, you can contact us by phone, fax or email.


CSL Behring Consumer Affairs
Phone: 1-888-508-6978
Fax: 610-290-9729
(Standard business hours are 9:00 am to 5:00 pm ET)


If you experience any  side effect(s) with a CSL Behring product, talk to your doctor, pharmacist or nurse. If you would like to report side effect(s) to CSL Behring, please contact us at:

CSL Behring US Pharmacovigilance
Phone: 1-866-915-6958
(Available 24 hours/day)


You are also encouraged to report side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.



Medical Information
Phone: 1-800-504-5434
Fax: 610-878-4550
(Standard business hours are 9:00 am to 5:00 pm ET)


Corporate Media Inquiries
Tom Hushen
Phone: 1-267-769-6728


Product-related Media Inquiries
James Freeman
Phone: 1-484-832-9045
(Standard business hours are 9:00 am to 5:00 pm ET)

Continue to

Burden of recurrent CV events

Find out about the significant healthcare costs associated with recurrent CV events post AMI1–4

Current standard of care post AMI

Current standard of care and newer therapies have lowered the long-term risk of recurrent CV events; however, data show that patients are still at risk during the 90-day high-risk period after an AMI5–12

Expert views

These resources are for healthcare professionals to learn more about the role of cholesterol efflux and support their patients after an AMI

Get the latest news

Sign up to receive news alerts and information about educational resources to help your patients through the 90-day high-risk period post AMI

By submitting this form, you are consenting to disclose any information provided, including your name, email address, telephone number, and any other information (collectively “Personal Information”) to CSL Behring and its representatives, agents, and contractors, including CSL Behring’s support program(s) (collectively “CSL Behring Entities”) and to receive communications with relevant information from CSL Behring Entities. You may be contacted by mail, email, telephone, and/or SMS/text message in relation to our business, products, services, and educational programs intended to benefit patients using or eligible to use CSL Behring therapies. You will have the ability to opt-out from receiving communications from CSL Behring Entities at any time. CSL Behring and CSL Behring Entities will not sell your personal information. CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy


AMI, acute myocardial infarction; CV, cardiovascular


1. Bakhai A et al. J Interv Cardiol 2012; 25:19–27.

2. Punekar RS et al. Clin Cardiol 2015; 38:483–491.

3. Zhao Z, Winget M. BMC Health Serv Res 2011; 11:35.

4. Chapman RH et al. BMC Cardiovasc Disord 2011; 11:11.

5. Schwartz GG et al. N Engl J Med 2018; 379:2097–2107.

6. Cannon CP et al. N Engl J Med 2015; 372:2387–2397.

7. Schwartz GG et al. JAMA 2001; 285:1711–1718.

8. Bhatt DL et al. N Engl J Med 2019; 380:11–22.

9. Bhatt DL et al. J Am Coll Cardiol 2019; 73:2791–2802.

10. Mehta SR et al. N Engl J Med 2019; 381:1411–1421.

11. Wallentin L et al. N Engl J Med 2009; 361:1045–1057.

12. Nair R et al. J Am Heart Assoc 2021; 10:e019270.


USA-GEN-0051 | August 2023